SKL 15508

Drug Profile

SKL 15508

Alternative Names: SKL 20540; SKL A4R; SKL15508

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SK biopharmaceuticals
  • Class Nootropics; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cognition disorders
  • Discontinued Mental disorders

Most Recent Events

  • 23 Mar 2018 Discontinued - Preclinical for Mental disorders in South Korea (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Mental-disorders in South Korea (PO)
  • 01 Jun 2015 SK biopharmaceuticals completes a phase I/II trial in for Cognition disorders iin schizophrenia in USA (NCT02205099)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top